Cost benefits of intraoperative cell salvage in radical cystectomy

Sarvpreet S Ubee, Ramaswamy Manikandan, Adinarayana R Gudimetla, Gurpreet Singh, Sarvpreet S Ubee, Ramaswamy Manikandan, Adinarayana R Gudimetla, Gurpreet Singh

Abstract

Objective: We have looked into the clinical and financial benefits of using intra-operative cell salvage (ICS) as a method to reduce the amount of autologous blood transfusion (ABT) requirement for our radical cystectomy (RC) patients.

Materials and methods: Fifteen consecutive patients undergoing radical cystectomy received cell salvaged blood (ICS), while 15 did not (NCS). The cost of using the cell saver, number of homologous transfusions, survival, and recurrences were recorded and compared using paired t-test and chi-square test between the two groups. A Dideco Electa® (Sorin Group, Electa, Italy) cell saver machine was used for all the patients in the ICS group and leukocyte filters were used on the salvaged blood before the autologous transfusion.

Results: The mean age was 63 years (53-72 years), 66 years (46-79 years) in ICS and NCS groups, respectively (P = 0.368). All 15 (100%) patients in the NCS group required an allogenic transfusion compared to 9/15 (60%) in the ICS group (P = 0.08). There was a significant reduction in the mean volume of allogenic blood transfused with the use of cell saver. Median follow-up was 23 and 21 months in the ICS and NCS group with 10 and 4 patients alive at last follow-up, respectively. There was a saving of 355 pounds per patient in the ICS group compared to the NCS group.

Conclusion: Our initial study shows that cell savage is feasible and safe in patients undergoing radical cystectomy. It does not adversely affect the medium term outcome of patients undergoing RC and is also cost effective.

Keywords: Blood transfusion; intraoperative cell salvage; radical cystectomy.

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Nieder AM, Manoharan M, Yang Y, Soloway MS. Intraoperative cell salvage during radical cystectomy does not affect long-term survival. Urology. 2007;69:881–4.
    1. Chang SS, Smith JA, Jr, Wells N, Peterson M, Kovach B, Cookson MS. Estimated blood loss and transfusion requirements of radical cystectomy. J Urol. 2001;166:2151–4.
    1. Nieder AM, Simon MA, Kim SS, Manoharan M, Soloway MS. Intraoperative cell salvage during radical prostatectomy is not associated with greater biochemical recurrence rate. Urology. 2005;65:730–4.
    1. Takayanagi A, Masumori N, Kobayashi K, Kunishima Y, Takahashi A, Itoh N, et al. Acute Normovolemic Hemodilution for Radical Retropubic Prostatectomy and Radical Cystectomy. Urology. 2008;72:401–5.
    1. Cárdenas-Turanzas M, Cooksley C, Kamat AM, Pettaway CA, Elting LS. Gender and age differences in blood utilization and length of stay in radical cystectomy: A population-based study. Int Urol Nephrol. 2008;40:893–9.
    1. Albers P, Heicappell R, Schwaibold H, Wolff J; German Association of Urological Oncology, Subdivision of the German Cancer Society. Erythropoetin in urologic oncology. Eur Urol. 2001;39:1–8.
    1. Lee KL, Freiha F, Presti JC, Jr, Gill HS. Gender differences in radical cystectomy: Complications and blood loss. Urology. 2004;63:1095–9.
    1. Hollenbeck BK, Miller DC, Taub D, Dunn RL, Khuri SF, Henderson WG, et al. Identifying risk factors for potentially avoidable complications following radical cystectomy. J Urol. 2005;174:1231–7.
    1. Berrum-Svennung I, Hedelin H, Holmäng S. Costs of radical cystectomy. Scand J Urol Nephrol. 2005;39:36–41.
    1. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine, first of two parts: Blood transfusion. N Engl J Med. 1999;340:438–47.
    1. Autologous blood transfusions. Council on Scientific Affairs. JAMA. 1986;256:2378–80.
    1. Goodnough LM, Grishaber JE, Birkmeyer JD, Monk TG, Catalona WJ. Efficacy and cost-effectiveness of autologous blood predeposit in patients undergoing radical prostatectomy procedures. Urology. 1994;44:226–31.
    1. Monk TG, Goodnough LT, Brecher ME, Pulley DD, Colberg JW, Andriole GL, et al. Acute normovolemic hemodilution can replace preoperative autologous blood donation as a standard of care for autologous blood procurement in radical prostatectomy. Anesth Analg. 1997;85:953–8.
    1. Monk TG, Goodnough LT, Birkmeyer JD, Brecher ME, Catalona WJ. Acute normovolemic hemodilution is a cost-effective alternative preoperative autologous blood donation by patients undergoing radical prostatectomy. Transfusion. 1995;35:559–5.
    1. Atallah MM, Banoub SM, Saied MM. Does timing of hemodilution influence the stress response and overall outcome? Anesth Analg. 1993;76:113–7.
    1. Park KI, Kojima O, Tomoyoshi T. Intra-operative autotransfusion in radical cystectomy. Br J Urol. 1997;79:717–21.
    1. Pisters LL, Wajsman Z. Use of predeposit autologous blood and intraoperative autotransfusion in urologic cancer surgery. Urology. 1992;40:211–5.
    1. Klimberg I, Sirois R, Wajsman Z, Baker J. Intraoperative autotransfusion in urologic oncology. Arch Surg. 1986;121:1326–9.
    1. Stoffel JT, Topjian L, Libertino JA. Analysis of peripheral blood for prostate cells after autologous transfusion given during radical prostatectomy. BJU Int. 2005;96:313–5.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera